Phase 2 Alzheimer's Disease Trial, Recruiting NCT04576793 Sponsor: Columbia University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT04576793
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 50 years of age or older at the time of screening
  • At screening, you either have no memory or thinking problems, or you have been diagnosed with a specific type of Alzheimer's disease (amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia)
  • Your level of memory or thinking difficulty must fall within a specific range on a standard rating scale used by doctors (called the Clinical Dementia Rating scale)
  • If you are not able to give your own consent to participate, you must have someone (such as a family member) who can make decisions on your behalf
  • You must be able to read, write, and speak English or Spanish
  • You must be available and able to attend all scheduled appointments and complete all required tests
  • In the opinion of the lead researcher, you are likely to follow the study rules and complete the full study

Who may not be able to join:

  • You have a history of any brain condition other than Alzheimer's disease, including evidence of a past stroke seen on a brain scan
  • You have serious medical conditions that would make the study procedures unsafe, such as uncontrolled epilepsy or multiple serious injuries
  • You are unable to have an MRI scan for medical reasons
  • You are unable to physically enter an MRI scanner, for example due to severe obesity or a fear of enclosed spaces (claustrophobia)
  • You have taken part in other research involving radiation in the past year, and combining that with this study would put you over the safe limit
  • Certain medications may disqualify you, as decided by the lead researcher on a case-by-case basis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Patrick J. Lao, PhD, Columbia University

Phone: 212-305-9079

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
17 November 2020
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

11C-ER176 Standardized Uptake Value Ratio; 18F-MK6240 Standardized Uptake Value Ratio

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov